HomeCompareMYCOF vs DIVO

MYCOF vs DIVO: Dividend Comparison 2026

MYCOF yields 151.75% · DIVO yields 6.62%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MYCOF wins by $26.47M in total portfolio value
10 years
MYCOF
MYCOF
● Live price
151.75%
Share price
$1.32
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.50M
Annual income
$11,538,455.63
Full MYCOF calculator →
DIVO
DIVO
● Live price
6.62%
Share price
$44.00
Annual div
$2.91
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$31.0K
Annual income
$1,008.47
Full DIVO calculator →

Portfolio growth — MYCOF vs DIVO

📍 MYCOF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMYCOFDIVO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MYCOF + DIVO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MYCOF pays
DIVO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MYCOF
Annual income on $10K today (after 15% tax)
$12,898.33/yr
After 10yr DRIP, annual income (after tax)
$9,807,687.29/yr
DIVO
Annual income on $10K today (after 15% tax)
$562.67/yr
After 10yr DRIP, annual income (after tax)
$857.20/yr
At 15% tax rate, MYCOF beats the other by $9,806,830.09/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MYCOF + DIVO for your $10,000?

MYCOF: 50%DIVO: 50%
100% DIVO50/50100% MYCOF
Portfolio after 10yr
$13.26M
Annual income
$5,769,732.06/yr
Blended yield
43.50%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MYCOF buys
0
DIVO buys
0
No recent congressional trades found for MYCOF or DIVO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMYCOFDIVO
Forward yield151.75%6.62%
Annual dividend / share$2.00$2.91
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$26.50M$31.0K
Annual income after 10y$11,538,455.63$1,008.47
Total dividends collected$24.54M$8.4K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: MYCOF vs DIVO ($10,000, DRIP)

YearMYCOF PortfolioMYCOF Income/yrDIVO PortfolioDIVO Income/yrGap
1← crossover$25,875$15,174.51$11,362$661.96+$14.5KMYCOF
2$64,380$36,694.66$12,860$702.91+$51.5KMYCOF
3$154,217$85,329.77$14,504$743.56+$139.7KMYCOF
4$356,039$191,027.06$16,303$783.73+$339.7KMYCOF
5$793,132$412,170.66$18,268$823.31+$774.9KMYCOF
6$1,706,759$858,106.90$20,408$862.17+$1.69MMYCOF
7$3,552,006$1,725,774.37$22,737$900.20+$3.53MMYCOF
8$7,157,264$3,356,617.38$25,266$937.31+$7.13MMYCOF
9$13,979,354$6,321,081.53$28,008$973.42+$13.95MMYCOF
10$26,496,364$11,538,455.63$30,977$1,008.47+$26.47MMYCOF

MYCOF vs DIVO: Complete Analysis 2026

MYCOFStock

Noveris Health Sciences Inc. is a biotechnology company, which engages in the research, drug development, and clinical trials of psilocybin products. The company was founded by Parente Carman, Damon Michaels, and Robert Roscow on September 27, 2013 and is headquartered in Vancouver, Canada.

Full MYCOF Calculator →

DIVOETF

DIVO is an ETF of high-quality large cap companies with a history of dividend and earnings growth, along with a tactical covered call* strategy on individual stocks. DIVO is strategically designed to offer high levels of total return on a risk-adjusted basis.

Full DIVO Calculator →
📬

Get this MYCOF vs DIVO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MYCOF vs SCHDMYCOF vs JEPIMYCOF vs OMYCOF vs KOMYCOF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.